Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 22 of 37, showing 5 Applications out of 183 total, starting on record 106, ending on 110

# Protocol No Study Title Investigator(s) & Site(s)

106.

ECCT/21/05/05   The “EMPATHY” Trial
    A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19.       
Principal Investigator(s)
1. DR LUCAS OTIENO TINA
2. Dr. Bernhards Ragama Ogutu
3. Dr Deborah Chepngeno Langat
4. Dr Videlis Nduba Nduba
5. Dr Janet Oyieko
Site(s) in Kenya
1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
2. Kenyatta University Teaching Referral and Research Hospital (KUTRRH) (Nairobi City county)
3. Kenya Medical Research Institute/US Army Medical Research Directorate-Kenya-Kericho (Kericho county)
4. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county)
5. KEMRI-USAMRD-A, Kisumu Field Station (Kisumu county)
 
View

107.

ECCT/21/05/03   Adapt Out COVID
    Adaptive Platform Treatment trial for Outpatients with COVID-19   
Principal Investigator(s)
1. Kawango Agot
Site(s) in Kenya
1. Kenya Impact and Research Development Organization (K-IRDO) (Kisumu county)
2. KEMRI WALTER REED (Kericho county)
3. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county)
4. Kenya Medical Research Institute (Kisumu county)
 
View

108.

ECCT/21/03/02   PB-SAM
    Pancreatic Enzymes and Bile Acids: A Non-Antibiotic approach to Treat Intestinal Dysbiosis in Acutely Ill Severely Malnourished Children.   
Principal Investigator(s)
1. Robert Bandsma
Site(s) in Kenya
1. Kilifi County Hospital (Kilifi county)
2. Coast General Hospital (Mombasa county)
3. Mbagathi Hospital (Nairobi City county)
4. Migori County Hospital (Migori county)
 
View

109.

ECCT/21/03/01   Recombinant COVID-19 vaccine
    A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells), for the prevention of COVID-19 in adults aged 18 years and older   
Principal Investigator(s)
1. Walter Jaoko Jaoko
Site(s) in Kenya
KAVI-institute of Clinical Research
 
View

110.

ECCT/21/02/03   VAC078
    A Phase III randomized, controlled, multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria.   
Principal Investigator(s)
1. Mainga Patience Mayeso Hamaluba
2. Jean Bosco Ouedraogo
3. Halidou Tinto
4. Alassane Dicko
5. Ally Olotu
Site(s) in Kenya
KEMRI Wellcome Trust Research Programme
 
View